Allogeneic hematopoietic cell transplantation (HCT)

HCT is an effective therpay for hematological malignancies but it is limited by acute graft-versus-host disease (GVHD) GVHD arises wehn donor T cells respond to genetically defined proteins on host cells. 

Allogeneic hematopietic stem cell transplantation (HSCT)

HSCT generally involves transferring the hematopoietic cells from an immunologically compatible healthy person (the donor) to a pateint after a conditioning regimen. Healthy hematopoietic stem cells (HSC) can replace the damaged hematopoietic tissue of a patietn, and specific donor derived immune cells can have a therapeutic effct on cancer, infections, and immunoglogical diseases. US Patent 10,857,183

Dimov (US 10,857,183 and 10,300,090) discloses a method of treating a disease that includes administering a cell population which include HSPC along with T memory, Treg and naive conventional alphabeta-T cells at various concentrations. The HSPC refers to hematopoietic stem cells that express increased levels of phenotypic markers CD34, CD133 and CD90. The method also includes a method of producing the various populations. For example, a sample can be contacted with a binding molecule for CD34 to enrich for CD34+ cells, recovering the popuation of CD34 depleted which are then contacted with a molecule tht binds CD25 to enrich for CD25+ cells and CD25-depleted cells which are then contacted with a molecule tht binds CD45RA to enrich for CD45RA+ and CD45RA depleted cells. The population enriched for CD34+ cell, CD25+ cells and CD45 depleted cells can be formulated as a therapeutic formulation. The cell populations have been sculpted to enrich the number of cells with therapeutic benefit and deplete the cell populations that are detrimental in a graft receipient.